Roivant Sciences
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $4,475 | $55,132 | $28,930 | $37,140 |
Gross Profit | 2,423 | 51,154 | 24,518 | 33,472 |
EBITDA | -222,565 | -179,072 | 5,113,166 | -310,831 |
EBIT | -224,383 | -183,955 | 5,107,941 | -316,216 |
Net Income | -230,184 | 95,297 | -151,115 | 5,096,184 |
Net Change In Cash | 4,475 | 55,132 | 28,930 | 37,140 |
Free Cash Flow | -267,802 | -193,794 | -108,806 | -210,807 |
Cash | 1,969,914 | 5,678,514 | 6,535,706 | 6,670,810 |
Basic Shares | 735,470 | 781,627 | 802,859 | 844,461 |
Annual Financials
| Values in thousands | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
Revenue | $124,795 | $61,280 | $55,286 | $23,795 |
Gross Profit | 109,235 | 48,152 | 46,320 | 21,738 |
EBITDA | 4,310,244 | -1,178,009 | -916,705 | -895,737 |
EBIT | 4,288,208 | -1,196,866 | -922,637 | -1,070,898 |
Net Income | 4,348,926 | -1,009,030 | -845,262 | -809,234 |
Net Change In Cash | 124,795 | 61,280 | 55,286 | 23,795 |
Cost of Revenue | -388,200 | -67,642 | ||
Free Cash Flow | -766,650 | -856,083 | -695,165 | -557,944 |
Cash | 6,535,706 | 1,676,813 | 2,060,400 | 2,055,044 |
Basic Shares | 831,049 | 712,791 | 669,753 | 684,789 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.31 |
2024-06-30 | $0.12 |
2024-03-31 | -$0.19 |
2023-12-31 | -$0.30 |
